arrow
I

Ioanna Dima

National and Kapodistrian University of Athens
H指数:15
被引数:1,163

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

HDL cholesterol as an associate of prevalent coronary artery disease in heterozygous Familial hypercholesterolemia beyond LDL cholesterol

HDL胆固醇作为杂合子家族性高胆固醇血症中除LDL胆固醇之外与患病冠状动脉疾病相关的因素

2025-09-200
PRE
Endothelial function and peak heart rate in normal-weight women with polycystic ovary syndrome and normal-weight controls

内皮功能和高体重女性多囊卵巢综合征患者及正常体重对照组的峰值心率

2025-09-100
PRE
Beyond lipid levels: unraveling the hypertensive factor in familial hypercholesterolemia. The HELLAS-FH registry

超越血脂水平:解析家族性高胆固醇血症中的高血压因素。HELLAS-FH登记研究

2025-07-210
PRE
Exploring the correlation between triglyceride levels and atherosclerotic cardiovascular disease prevalence in adults with familial hypercholesterolemia: Insights from a cross-sectional analysis in the HELLAS-FH registry

探讨家族性高胆固醇血症成人中甘油三酯水平与动脉粥样硬化性心血管疾病患病率的相关性:来自HELLAS-FH登记研究的横断面分析结果

2025-01-310
PRE
Lipoprotein(a) in familial dyslipidemias: The effect on cardiovascular prognosis in patients with familial hypercholesterolemia or familial combined hyperlipidemia

脂蛋白(a)在家族性脂质代谢紊乱中的作用:在家族性高胆固醇血症或家族性混合型高脂血症患者中心血管预后的影响

2025-01-230
PRE
The effect of lipid-lowering treatment on indices of MASLD in familial hypercholesterolemia patients
2024-12-010
PRE
Association between lipoprotein(a) concentrations and atherosclerotic cardiovascular disease risk in patients with familial hypercholesterolemia: an analysis from the HELLAS-FH
2022-03-093
PRE
LDL cholesterol target achievement in heterozygous familial hypercholesterolemia patients according to 2019 ESC/EAS lipid guidelines: Implications for newer lipid-lowering treatments
2021-12-0120
PREAI
Very high-risk familial hypercholesterolaemia patients in real life: The remaining gap in achieving the current LDL-C targets despite the use of PCSK9 inhibitors

现实生活中的极高危家族性高胆固醇血症患者: 尽管使用PCSK9抑制剂,但在实现当前ldl-c目标方面仍存在差距

2020-09-0113
PREAI